Trial Profile
Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NIVEAL
- 08 Nov 2019 Status changed from recruiting to completed.
- 02 Mar 2018 Planned End Date changed from 1 Feb 2020 to 1 Jan 2020.
- 02 Mar 2018 Planned primary completion date changed from 1 Feb 2020 to 1 Jan 2020.